Shaily Q2 FY27 slides: healthcare surge drives 24% revenue growth

Shaily Engineering Plastics Ltd. reported a 24% surge in Q2 FY27 revenue, highlighting a significant shift toward healthcare manufacturing. The India-based precision plastics company now sees healthcare segment contributions comprising 55% of total sales. The company's shares rose 3.5% to trade near Rs. 3,164.25 following the presentation.

Q2 FY27 revenue reached Rs. 319.5 crores, up from Rs. 256.7 crores in the previous year. EBITDA increased by 25% to Rs. 101.8 crores, and profit after tax rose 20% to Rs. 61.3 crores. Healthcare revenue surged 78% year-over-year to Rs. 175.1 crores in Q2 FY27, while consumer segment declined 14% to Rs. 115.9 crores. The industrial segment saw a 23% growth to Rs.

28.6 crores. Strategic developments include new contracts for Semaglutide pens, plans for a new manufacturing facility in Abu Dhabi, and a new product platform, the Shaily Al Toby™ Reusable auto-injector. Operational efficiency showed improvement in machine utilization, revenue mix, and capital efficiency, with RoCE and RoE both increasing.

CARE Ratings upgraded Shaily's short-term bank facilities to CARE A1+ and reaffirmed the CARE A+ rating on long-term facilities.